However, the intra-tumoral heterogeneity in HER2 expression on tissue biopsy may represent a significant problem, and the use of a plasma-based method of detection could be a strategy to overcome this issue and identify a more complete molecular profile for each tumor. The gene discussed is ERBB2; the disease is neoplasm.